Establishing New Mechanisms for Public-Private Partnerships to Address Common Challenges in Drug R&D

Abstract

Objective To study the cases of public-private partnerships (PPPs) commonly used in Europe Union and the United States to solve common challenges such as the decline in drug R&D efficiency, and to provide reference for developing countries to deal with these challenges in drug R&D. Methods Multiple case study method was used to make a comparative analysis of three PPP models in European Union and the United States. Results and Conclusion Third-party conveners, project-based cooperation models, and PPP funding mechanisms were key elements of PPP models in European and the United States. The developing countries should establish new PPP mechanisms to solve common challenges in drug R&D in their countries based on national conditions and key elements of PPP models.

Keywords

public-private partnership (PPP) / drug innovation / Eroom’s Law

References

[1] Sullivan R. Cancer medicines: A private vice for public benefit?[J]. E Cancer Medical Science, 2024, 18: ed131.

[2] Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency[J]. Nature Reviews Drug Discovery, 2012, 11 (3): 191-200.

[3] Kuzma E, Padilha LS, Sehnem S, et al. The relationship between innovation and sustainability: A meta-analytic study[J]. Journal of Cleaner Production, 2020, 259: 120745.

[4] Hall EG, Krenning TM, Reardon RJ, et al. A reconsideration of university gap funds for promoting biomedical entrepreneurship[J]. Journal of Clinical and Translational Science, 2022, 6 (1): e28.

[5] Maxfield KE, Buckman-Garner S, Parekh A. The role of public-private partnerships in catalyzing the critical path[J]. Clinical and Translational Science, 2017, 10 (6): 431.

[6] Laverty H, Gunn M, Goldman M. Improving R&D productivity of pharmaceutical companies through public-private partnership: Experiences from the Innovative Medicines Initiative[J]. Expert Review of Pharmacoeconomics & Outcomes Research, 2012, 12 (5): 545-548.

[7] Davis AM, Engkvist O, Fairclough RJ, et al. Public-private partnerships: Compound and data sharing in drug discovery and development[J]. SLAS Discovery: Advancing the Science of Drug Discovery, 2021, 26 (5): 604-619.

[8] Sharma S. Public-private partnerships: Bringing high-quality healthcare to the world[J]. Accelerating Global Health, 2023, 2 (1): 72-81.

[9] Baldoni J, Begoli E, Kusnezov DF, et al. Solving hard problems with AI: Dramatically accelerating drug discovery through a unique public-private partnership[J]. Journal of Commercial Biotechnology, 2020, 25 (4): 42.

[10] Jia Kang, Sun Jie. The concept, origin and function of public-private partnership (PPP)[J]. Review of Economic Research, 2014 (13): 4-16.

[11] OECD. Eroom’s Law and the Decline in the Productivity of Biopharmaceutical R&D[M]. Paris: OECD Publishing, 2023.

[12] Zheng Xiaonan, Huang Wenlong. Analysis of PPP model and operation mechanism for new drug research and development in developing countries[J]. Science & Technology and Economy, 2010, 23 (4): 82-85.

[13] Gunn M, Lim M, Cross D, et al. Benchmarking the scientific output of the innovative medicines initiative[J]. Nature Biotechnology, 2015, 33 (8): 811-812.

[14] Goldman M, Compton C, Mittleman BB. Public-private partnerships as driving forces in the quest for innovative medicines[J]. Clinical and Translational Medicine, 2013, 2: 2.

[15] Komura H, Watanabe R, Kawashima H, et al. A public-private partnership to enrich the development of in silico predictive models for pharmacokinetic and cardiotoxic properties[J]. Drug Discovery Today, 2021, 26 (5): 1275-1283.

[16] FDA. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products[R]. 2004.

[17] CDER. MAPP 4100.2[EB/OL]. (2017-01-03)[2024-07-01]. https://www.fda.gov/media/167374/download.

[18] O’Rourke D, Coll-Padrós N, Bradshaw A, et al. The innovative medicines initiative neurodegeneration portfolio: From individual projects to collaborative networks[J]. Frontiers in Neurology, 2022, 13: 994301.